AIPPI Position Paper: TRIPS Agreement and the COVID-19 Waiver
"AIPPI is pleased to contribute its thoughts on this important issue and trusts that the discussions at the WTO TRIPS Council will result in an appropriate global and balanced approach," said Anne Marie Verschuur, Reporter General of AIPPI.
"For several years now, AIPPI members and in particular our TRIPS and Pharma Committee members have been extensively studying the role of intellectual property in helping to address health issues affecting the global community. The COVID-19 pandemic underscores our need for a reliable framework supported by all stakeholders, which encourages an urgent response to critical health challenges enabled by the recognition of game-changing innovations,"
Charles Boulakia, Vice Chairperson of the AIPPI Pharma Committee noted that, "Our AIPPI Pharma Committee includes 52 members; 44 members voted in support of the paper with no members against. All are intellectual property professionals with an excellent understanding of the issues, from all over the world, including some of the countries most affected by the current pandemic. As a Canadian, I can completely understand the frustration people are currently having with accessibility to COVID-19 vaccines. However, it's important to not throw the baby out with the bath water… The current intellectual property system is carefully thought out and there are already provisions in place in most countries for exceptional circumstances. We need a robust IP system to ensure that there is adequate incentive for research and development to address the next pandemic".
The position paper can be read in full on the AIPPI website: www.aippi.org.
The International Association for the Protection of Intellectual Property, known as AIPPI (Association Internationale pour la Protection de la Propriété Intellectuelle)
Find out more at http://www.aippi.org
Diarmuid De Faoite